Showing 101 - 120 results of 153,996 for search '(( 2 a decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (nn decrease)) ))', query time: 2.02s Refine Results
  1. 101
  2. 102
  3. 103

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  4. 104

    Blocking of MC1R, MC2R or MC5R causes a decrease in the enucleation ratio of erythrocytes. by Eriko Simamura (720229)

    Published 2015
    “…The enucleation ratio was decreased in the erythroblasts treated with anti-MC1R nAb, anti-MC2R nAb or anti-MC5R nAb. *, <i>P <</i> 0.0001, each point versus control. n = 3; error bars, s.e.m. …”
  5. 105

    Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

    Published 2011
    “…Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-βtreatment. …”
  6. 106

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113

    Supplementary Material for: Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times by Lannes F. (11465377)

    Published 2021
    “…Mean length of stay did not differ significantly between ERAS and non-ERAS groups (12.7 ± 6.2 and 13.1 ± 5.7 days, respectively; <i>p</i> = 0.743). …”
  14. 114

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”
  15. 115
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120